

Comparison of antifungal activity of fluconazole and clove leaf essential oil on *Candida* species isolate in HIV/AIDS patients with oral candidiasis

by Retno Widyowati

Submission date: 14-Apr-2023 03:58AM (UTC+0800)

Submission ID: 2063764414

File name: C-27_artikel.pdf (235.11K)

Word count: 4707

Character count: 26221

How to Cite:

Harningtyas, C. D., Murtiastutik, D., Citrashanty, I., Endraswari, P. D., Widyowati, R., Ervianti, E., Sawitri, S., & Rahmadewi, R. (2022). Comparison of antifungal activity of fluconazole and clove leaf essential oil on *Candida* species isolate in HIV/AIDS patients with oral candidiasis. *International Journal of Health Sciences*, 6(S6), 3067–3077.
<https://doi.org/10.53730/ijhs.v6nS6.11207>

38

Comparison of antifungal activity of fluconazole and clove leaf essential oil on *Candida* species isolate in HIV/AIDS patients with oral candidiasis

Citra Dwi Harningtyas

Department of Dermatology and Venereology, Universitas Airlangga, Dr, Soetomo General Academic Teaching Hospital, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

Dwi Murtiastutik

Department of Dermatology and Venereology, Universitas Airlangga, Dr, Soetomo General Academic Teaching Hospital, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

*Corresponding author email: dwimurtiastutik@yahoo.co.id

Irmadita Citrashanty

Department of Dermatology and Venereology, Universitas Airlangga, Dr, Soetomo General Academic Teaching Hospital, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

Pepy Dwi Endraswari

Department of Clinical Microbiology, Universitas Airlangga, Dr, Soetomo General Academic Teaching Hospital, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

Retno Widyowati

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

Evy Ervianti

Department of Dermatology and Venereology, Universitas Airlangga, Dr, Soetomo General Academic Teaching Hospital, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

Sawitri

Department of Dermatology and Venereology, Universitas Airlangga, Dr, Soetomo General Academic Teaching Hospital, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

International Journal of Health Sciences ISSN 2550-6978 E-ISSN 2550-696X © 2022.

Manuscript submitted: 9 March 2022, Manuscript revised: 27 May 2022, Accepted for publication: 18 June 2022

3067

Rahmadewi

Department of Dermatology and Venereology, Universitas Airlangga, Dr, Soetomo General Academic Teaching Hospital, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

Abstract—Current treatment guidelines include fluconazole as the main therapeutic option for treating oral candidiasis infection in HIV/AIDS patients, but resistance increases. Several in vitro studies have shown that clove leaf essential oil with the main content of eugenol can be an alternative therapy for oral candidiasis that is resistant to fluconazole. This study was conducted to determine the zone of inhibition of clove leaf essential oil and fluconazole against *Candida* isolates species that cause oral candidiasis in HIV/AIDS patients. This study showed that the average fluconazole disk 25 µg/mL inhibition zone in 20 isolates of *Candida albicans* species was larger than *non-albicans Candida* species. The zone of inhibition of clove leaf essential oil was significantly lower than that of fluconazole ($p < 0.05$), except at a concentration of 15% against *non-albicans Candida* isolates. Clove leaf essential oil has an antifungal effect that can inhibit the growth of *Candida* species, so it can be considered an alternative antifungal therapy. Clove leaf essential oil concentration of 15% showed no significant differences in antifungal activity with the standard drug fluconazole in isolates of *non-albicans Candida* species.

Keywords—oral candidiasis, fluconazole, clove leaf, antifungal, HIV/AIDS.

Introduction

Oral candidiasis is one of the most common skin and mucosal manifestations found in patients with HIV/AIDS. Nearly 90% of patients with HIV/AIDS have experienced oral candidiasis during their illness (Murtiastutik & Maharani, 2019). The average prevalence in Europe and the United States is 28% and 30%, respectively. The prevalence of oral candidiasis has also been reported in Africa at 51% and in Asia at 39% (Tappuni, 2020). Oral candidiasis can be a morbidity and can interfere in the quality of life in HIV/AIDS patients because it often lasts longer, has a high recurrence rate, and has more severe clinical symptoms (Murtiastutik et al., 2021; Sakkas et al., 2016).

Among various species, *C. albicans* accounts for more than 90% of cases associated with severe fungal infections and causes candidiasis in immunocompetent patients (Alshaik & Kahkashan, 2017). The proportion of *Candida* infections caused by *C. albicans* in HIV/AIDS patients has shifted to *non-albicans Candida* species, and it may be due to high rates of antifungal drug resistance (Berkow & Lockhart, 2017; Murtiastutik et al., 2021). Research by Moges showed that the resistance rate of several antifungal agents by disc diffusion test in HIV/AIDS patients with oral candidiasis in Ethiopia in 2013-2014 showed that all isolates of *Candida* spp. found that 12.3% were resistant to

fluconazole, 8.4% to ketoconazole, and 1.3% to nystatin (Mulu et al., 2013). Current treatment guidelines include fluconazole as the main therapeutic option for treating oral candidiasis infection in HIV/AIDS patients (Berkow & Lockhart, 2017; Dar et al., 2015).

The existence of resistance to the main antifungal drugs urges research to find natural ingredients that can be attractive alternatives to antifungals. Most essential oils obtained from many tropical and subtropical plants contain eugenol as the main antifungal component (Schmidt et al., 2007). The concentration of eugenol in several plants is different. In the literature, it is stated that clove (*Syzygium aromaticum* L.) is considered the highest source of eugenol (45–90%) (Gupta & Prakash, 2021). Research conducted by Bhuiyan and colleagues compared the essential oil content of clove leaves and flowers, showing that the eugenol content was higher in clove leaves, namely 74.28%, while in flowers, as much as 49.71% (Bhuiyan et al., 2010). The most common methods for the isolation of eugenol are steam and water distillation (Khalil et al., 2017).

Research by Musta and Nurliana in 2019 regarding the effectiveness of clove leaf oil as antifungal *Candida albicans* showed antifungal activity for each concentration variation of 100%, 75%, 50%, and 25%, respectively, 14.2 mm, 12.2 mm, 10, 8mm and 10.4mm. The minimum concentration of clove leaf oil as antifungal *Candida albicans* is 17.86%. The clove leaves used were obtained from Bombana Regency, Southeast Sulawesi (Musta & Nurliana, 2019). A similar study was also conducted by Khansa (2019) who used clove flower essential oil from plantations in Yogyakarta. The diameter of the inhibition zone of clove flower essential oil at a concentration of 0.5% was 7.79 mm, a concentration of 1.0% was 12.02 mm, a concentration of 1.5% was 12.80 mm and a concentration of 2.0% was 13.96mm. This shows that the higher the clove flower essential oil concentration, the larger the resulting inhibition zone (Khansa, 2019). Variations in components and composition depend on the variety, agro-ecological conditions, pre-treatment, processing, and extraction method (Nurdjannah & N., 2012).

Clove oil has considerable antifungal activity against human fungal pathogens, including fluconazole-resistant strains. Clove essential oil can inhibit dermatophyte, *Aspergillus* and *Candida*, thus meeting the criteria for broad-spectrum agents (Alshaik & Kahkashan, 2017). Based on these data, this study aimed to compare the inhibitory of clove leaf essential oil (*Syzygium aromaticum*) and fluconazole *in vitro*.

Method

The research design used in this study was an experimental laboratory to compare the antifungal activity of clove leaf essential oil (*Syzygium aromaticum* L.) with fluconazole 25 µg/mL. There were 20 *Candida albicans* isolates and 20 non-*albicans Candida* isolates from the oral cavity of HIV/AIDS patients hospitalized at the Infectious Disease Intermediate Treatment Unit (UPIPI) RSUD Dr. Soetomo Surabaya from April – July 2019, which was reactivated. The clove leaf essential oil concentration based on the former study was 5%, 10%, and 15%. The antifungal activity was evaluated paper discs or blank discs using the disk diffusion method. These data were entered into a data collection sheet and

analyzed with SPSS (Statistical Package for Social Sciences). This research has obtained ethical approval from the Ethics Committee of Dr. Soetomo General Academic Teaching Hospital Surabaya (0286/KEPK/X/2021).

Results

This study showed that the average fluconazole disk 25 µg/mL inhibition zone in 20 isolates of *Candida albicans* species was 29.31±7.847 mm, while in 20 isolates of non-*albicans Candida* species was 23.97±8.682 mm. The average inhibition zone of clove leaf essential oil concentrations of 5%, 10% and 15% in 20 isolates of *Candida albicans* species were 10.83±3.135 mm, 18.00±4.141 mm and 23.69±7.062 mm, respectively. While the 20 isolates of non-*albicans Candida* species were 9.54±6.942 mm, 17.93±5.543 mm and 21.36±6.313 mm, respectively (Table 1). Four samples (10%) of isolates showed resistance to the antifungal fluconazole 25 g/mL, one from *Candida albicans* species and three from species non-*albicans Candida* (one from *C. glabrata* species, two from *C. krusei* species).

Table 1
Distribution of mean diameter of the inhibition zone of fluconazole and clove leaf essential oil (*Syzygium aromaticum* L.) 5,10 and 15% in isolates *Candida* spp

Antifungal type (n=40)	Average inhibition zone (mm)	
	± Standart Deviation (SD)	
	<i>Candida albicans</i> (n=20)	non- <i>albicans Candida</i> (n=20)
Flukonazol 25 µg/mL	29.31 ± 7.847	23.97 ± 8.682
Clove leaf essential oil 5%	10.83 ± 3.135	9.54 ± 6.942
Clove leaf essential oil 10%	18.00 ± 4.141	17.93 ± 5.543
Clove leaf essential oil 15%	23.69 ± 7.062	21.36 ± 6.313

The comparative analysis of the average inhibition zone between fluconazole and clove leaf essential oil concentrations of 5%, 10%, and 15% on 20 isolates of *Candida albicans* species obtained significant differences with p-value, respectively 0.000; 0.000; 0.018. The mean diameter of the fluconazole inhibition zone was greater than that of clove leaf essential oil (Table 2).

Table 2
Comparison of the mean diameter of the inhibition zone of fluconazole with clove leaf essential oil (*Syzygium aromaticum* L.) in *Candida albicans* isolates

Antifungal type (n=20)	Average inhibition zone (mm) ± Standart Deviation (SD)	p-value
Flukonazol 25 µg/mL	29.31±7.847	-
Clove leaf essential oil 5%	10.83±3.135	0.000
Clove leaf essential oil 10%	18.00±4.141	0.000
Clove leaf essential oil 15%	23.69±7.062	0.018

The results of the comparative analysis of the average inhibition zone between fluconazole and clove leaf essential oil on non-albicans *Candida* isolates showed significant differences in clove leaf essential oil concentrations of 5% and 10% (p values 0.000 and 0.021), where the mean diameter of the fluconazole inhibition zone was more prominent than clove leaf essential oil. Meanwhile, clove leaf essential oil with a concentration of 15% did not show a significant difference compared to fluconazole ($p=0.330$), where the mean diameter of the fluconazole inhibition zone was greater (Table 3).

Table 3
Comparison of the mean diameter of the inhibition zone of fluconazole with clove leaf essential oil (*Syzygium aromaticum* L.) in non-albicans *Candida* isolates

Antifungal type (n=20)	Average inhibition zone (mm) \pm Standart Deviation (SD)	p -value
Flukonazol 25 μ g/mL	23.97 \pm 8.682	-
Clove leaf essential oil 5%	9.54 \pm 6.942	0.000
Clove leaf essential oil 10%	17.93 \pm 5.543	0.021
Clove leaf essential oil 15%	21.36 \pm 6.313	0.330

Discussion

Fluconazole is a systemic antifungal used in oral candidiasis in HIV/AIDS patients. Changes in species that cause oral candidiasis lead to the emergence of resistance to fluconazole (William et al., 2011). The existence of resistance to antifungal drugs, especially fluconazole, urges research to be carried out to find natural ingredients that can be an antifungal alternative. Many essential oils are obtained from several tropical and subtropical plants, containing eugenol as the main antifungal component (Schmidt et al., 2007). The concentration of eugenol in several plants is different. In the literature, it is stated that clove (*Syzygium aromaticum* L.) is considered the highest source of eugenol (45–90%) (Gupta & Prakash, 2021).

The average fluconazole inhibition zone in 20 isolates of *Candida albicans* species was 29.31 \pm 7.847 mm, while in 20 isolates of non-albicans *Candida* species was 23.97 \pm 8.682 mm. This indicates that fluconazole 25 μ g/mL still has good antifungal activity in this study. When compared to the mean zone of inhibition between *Candida albicans* and non-albicans *Candida* species, it was found that fluconazole 25 μ g/mL gave a larger zone of inhibition in *Candida albicans* isolates than in non-albicans *Candida* isolates. This is consistent with the theory which states that immunocompromised conditions, comorbidities, use of broad-spectrum antibiotics, and practical use of antimycotic drugs such as fluconazole use in HIV patients are reported to be associated with an increase in non-albicans *Candida* strains and an increase in fluconazole-resistant *Candida albicans* strains (Pudjiati et al., 2018). Combined overexpression of CDR2 and ERG11 and mutations in the ERG11 gene were the genetic mechanism of fluconazole resistance in *Candida* isolated from HIV patients (Rosana et al., 2015).

The fluconazole sensitivity criteria or inhibition zone category used was the size of the inhibition zone according to the Clinical and Laboratory Standards Institute

(CLSI) standards for fluconazole. Sensitive results in the sensitivity test showed that the diameter of the inhibition zone was more than and equal to 19 mm. The zone of inhibition between 14 – 18 mm indicated a susceptible-dose-dependent (SDD), and the zone of inhibition less than 14 mm indicated resistance to the growth of *Candida* spp. in vitro (Sumalapao et al., 2018). In the in vitro inhibition zone test of 40 isolates of research subjects, four samples (10%) of isolates showed resistance to the antifungal fluconazole 25 µg/mL because it had an inhibitory zone diameter of 14 mm. Research conducted by Murtiastik et al. (2019) in Surabaya with the number of research subjects of HIV/AIDS patients, as many as 20 patients with 37 isolates of *Candida* species growing in culture, in the test for resistance of *Candida* species to fluconazole showed that 18 (48.6%) isolates were resistant to fluconazole. The most resistant isolates were non-albicans, with as many as 13 isolates (72.2%) (Murtiastutik & Maharani, 2019).

Isolate of *Candida* species that showed resistance to fluconazole were derived from one sample of *Candida albicans* species and three samples of non-albicans *Candida* species (1 from *C. glabrata* species, two from *C. krusei* species). In a laboratory-based population study, the resistance to fluconazole is more excellent in isolates of non-albicans *Candida* species than in *C. albicans*. During the last ten years, there has been documentation of intrinsic resistance toazole antifungals, especially fluconazole, in several non-albicans *Candida* species, especially isolates of *C. glabrata* and *C. krusei*. A study conducted by Sadeghi et al. (2018) evaluated the antifungal susceptibility of non-albicans *Candida* species isolated from various clinical samples in vitro to fluconazole. Although *C. krusei* exhibits intrinsic resistance to fluconazole, it is controversial whether the increased resistance rate is related to fluconazole prophylaxis or prior treatment (Sadeghi et al., 2018). The results of the study by Houshmandzad et al. (2022), which aimed to analyze the anticandidal activity of fluconazole (FLZ) against FLZ-resistant *C. krusei* strains showed that 16 (76.2%) *C. krusei* strains were resistant to fluconazole, except for five (23, 8%) clinical isolate which showed susceptible-dose-dependent (SDD) results (Houshmandzad et al., 2022).

The average inhibition zone of clove leaf essential oil (*Syzygium aromaticum* L.) concentrations of 5%, 10% and 15% in 20 isolates of *Candida albicans* species alone were 10.83±3.135 mm, 18.00±4.141 mm and 23.69±7.062 mm. While the 20 isolates of non-albicans *Candida* species were 9.54±6.942 mm, 17.93±5.543 mm and 21.36±6.313 mm. The formation of inhibition zones in the study showed that clove leaf essential oil had an antifungal activity that could inhibit the growth of *Candida* species in both *Candida albicans* and non-albicans *Candida*. Following the research conducted by Musta and Nurliana in 2019 regarding the kinetics study of the effectiveness of clove leaf oil as an antifungal *Candida albicans* using clove leaves taken from Southeast Sulawesi. This study's minimum concentration of clove leaf oil as an antifungal *Candida albicans* was 17.86% (Musta & Nurliana, 2019). A similar study was also conducted by Khansa (2019) using clove flower essential oil from plantations in Yogyakarta. The measurement of the diameter of the inhibition zone of clove flower essential oil concentration of 0.5% is 7.79 mm, concentration of 1.0% is 12.02 mm, concentration of 1.5% is 12.80 mm and concentration of 2.0% is 13.96 mm. This shows that the higher the clove flower essential oil concentration, the larger the inhibition zone produced (Khansa, 2019).

The sensitivity values of clove leaf essential oil (*Syzygium aromaticum* L.) cannot be compared with fluconazole because they do not have a sensitivity standard according to CLSI, so what can be compared in this study is the average diameter of the inhibition zone between clove leaf essential oil and fluconazole 25 µg/mL as standard therapy (positive control) in mm. Fluconazole 25 µg/mL showed the largest mean diameter of the inhibition zone in all *Candida* spp isolates. This shows that the standard antifungal drug fluconazole 25 µg/mL still provides antifungal activity in a larger zone of inhibition compared to clove leaf essential oil concentrations of 5%, 10% and 15%. In another way, the inhibition zone formed from clove leaf essential oil in fluconazole-resistant isolates in this study gave better results.

This can be the basis that clove leaf essential oil with the main content of eugenol can be an alternative therapy for oral candidiasis that is resistant to fluconazole. These results are supported by a similar study conducted by Pinto et al. (2009) to evaluate the antifungal activity of clove essential oil and its main component, eugenol, against *Candida* isolates. This study stated that clove essential oil and eugenol had considerable antifungal activity against *Candida*, including fluconazole-resistant strains, namely *C. krusei*, which was intrinsically resistant to fluconazole, and *C. glabrata*, whose resistance was easily induced. These results strengthen further investigation of clove essential oil and eugenol for clinical application to treat fungal infections (Pinto et al., 2009).

The test results of the comparative analysis of the mean fluconazole inhibition zone to clove leaf essential oil concentrations of 5%, 10%, and 15% in 20 isolates of *Candida albicans* obtained a significant difference (p-value <0.05), where the diameter of the fluconazole inhibition zone bigger. There was no significant difference (p value=0.330) when an analysis of the mean inhibition zone of fluconazole was performed against clove leaf essential oil with a concentration of 15% in 20 isolates of non-*albicans* *Candida*. This shows that the inhibition zone of clove leaf essential oil concentrations of 5%, 10%, and 15% is not better than fluconazole 25 µg/mL as the standard drug. However, clove leaf essential oil has an antifungal effect that can inhibit the growth of *Candida* species, so it can be considered an alternative antifungal therapy, especially clove leaf essential oil concentration of 15% which shows good activity, not significantly different from the standard drug fluconazole in isolates of non-*albicans* *Candida*.

A similar study by Fristiyanti (2019) was conducted to determine whether or not the difference between two concentrations of clove leaf extract was significant. It was found that the concentration groups of 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% had significant differences in reducing colony thickness of *Candida albicans*. However, the concentration of 0.6% extract and 0.6% fluconazole is not significantly different in reducing the thickness of *Candida albicans* colonies. This shows an inverse relationship, in which the higher the concentration of clove leaf ethanol extract given, the thinner the *Candida albicans* colonies that grow. In addition, it can be seen that the effective concentration that can reduce the thickness of *Candida albicans* colonies starts from a concentration of 0.1% in this study (Fristiyanti, 2019).

Several other factors can affect the antifungal activity, including the concentration of the extract, the content of antifungal compounds, the type of fungus inhibited, and the diffusion power. The inhibition zone formed can also be influenced by the concentration of the extract, where the higher the concentration, the larger the clear zone will be formed. The more concentrated the concentration, the more active compounds are contained, thus affecting the diameter of the inhibition zone formed on fungal growth (Andayani et al., 2014). The antifungal activity test method used can also have an effect. This study uses the diffusion method which is one method that is often used to test antifungal activity. The advantage of the diffusion method is that it is a fast and straightforward method to see the antifungal effect by looking at the diameter of the inhibition zone formed, but there are drawbacks to the disc diffusion method, namely that not all substances may be absorbed in the paper disc so that it can affect the inhibition zone formed (Jawetz & Adelberg, 2007).

Clove leaf oil has the most vigorous activity against clinical isolates of *Candida albicans*, which is characterized by the highest eugenol content that can inhibit pre-formed biofilm and *Candida albicans* biofilm formation. This compound is effective against the adaptive mechanism of *Candida albicans* biofilm resistance to fluconazole (Khan & Ahmad, 2012). Biofilm production was slightly higher in non-*albicans* *Candida*. Biofilm is a collection of microorganisms that adhere to the surface and are encased in an extracellular polysaccharide matrix produced by these microorganisms. Types of *Candida* spp. with a high ability to form biofilms are generally more virulent than others. Biofilms also play a role in resistance to antifungal drugs used, although the primary mechanism is still unknown (Williams et al., 2011).

Conclusion

Clove leaf essential oil has an antifungal effect that can inhibit the growth of *Candida* species. Although the mean inhibition zone formed on fluconazole was significantly more extensive than that of clove leaf essential oil, in isolates that showed resistance to fluconazole, clove leaf essential oil gave a larger diameter of the inhibition zone. In addition, clove leaf essential oil with a concentration of 15% showed no difference in antifungal activity with the standard drug fluconazole on isolates of non-*albicans* *Candida* species. It could be considered an antifungal alternative, especially for fluconazole-resistant strains.

Acknowledgments

The authors would like to express their gratitude to Department of Dermatology and Venereology, Dr. Soetomo General Academic Teaching Hospital, Surabaya, Indonesia; Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia; Department of Clinical Microbiology, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia.

References

Alshaik, N., & Kahkashan, P. (2017). Anti-candidal Activity and Chemical Composition of Essential Oil of Clove (*Syzygium aromaticum*). *Journal of*

- Essential Oil Bearing Plants, 20(4), 951–958.
<https://doi.org/10.1080/0972060X.2017.1375867>
- Andayani, A., Susilowati, A., & Pangastuti, A. (2014). Anti Candida minyak atsiri lengkuas putih (*Alpinia galanga*) terhadap *Candida albicans* penyebab candidiasis secara invitro. *El Vivo*, 2(2), 2014.
- Berkow, E. L., & Lockhart, S. R. (2017). Fluconazole resistance in *Candida* species: a current perspective. *Infect Drug Resist*, 10(1), 237–245.
<https://doi.org/10.2147/IDR.S118892>
- Bhuiyan, N. I., Begum, J., Nandi, N. C., & Akter, F. (2010). Constituents of the essential oil from leaves and buds of clove (*Syzygium caryophyllatum* (L.) Alston). *African Journal of Plant Science*, 4(11), 451–454.
- Dar, M. S., Sreedar, G., Shukla, A., Gupta, P., Rehan, A. D., & George, J. (2015). An in vitro study of antifungal drug susceptibility of *Candida* species isolated from human immunodeficiency virus seropositive and human immunodeficiency virus seronegative individuals in Lucknow population Uttar Pradesh. *J Oral Maxillofac Pathol*, 19(2), 205–211.
<https://doi.org/10.4103/0973-029X.164534>
- Fristiyanti, R. A. (2019). Uji Efektivitas Antijamur Ekstrak Etanol Daun Cengkeh (*Syzygium Aromaticum*) Terhadap Pertumbuhan *Candida Albicans* Secara In Vitro. Universitas Brawijaya.
- Gupta, C., & Prakash, D. (2021). Comparative Study of the Antimicrobial Activity of Clove Oil and Clove Extract on Oral Pathogens. *Dentistry – Open Journal*, 7(1), 12–15. <https://doi.org/10.17140/doj-7-144>
- Houshmandzad, M., Sharifzadeh, A., Khosravi, A., & Shokri, H. (2022). Potential antifungal impact of citral and linalool administered individually or combined with fluconazole against clinical isolates of *Candida krusei*. *Journal of Herbmед Pharmacology*, 11(2), 269–277.
<https://doi.org/10.34172/jhp.2022.32>
- Jawetz, M., & Adelberg. (2007). *Mikrobiologi Kedokteran* (23rd ed.). Jakarta: ISBN 978-979- 448-859-1.
- Khalil, A. A., Rahman, U. U., Khan, M. R., Sahar, A., Mehmood, T., & Khan, M. (2017). Essential oil eugenol: Sources, extraction techniques and nutraceutical perspectives. *RSC Advances*, 7(52), 32669–32681.
<https://doi.org/10.1039/c7ra04803c>
- Khan, M. S. A., & Ahmad, I. (2012). Antibiofilm activity of certain phytochemicals and their synergy with fluconazole against *Candida albicans* biofilms. *J Antimicrob Chemother*, 67(3), 618–621.
<https://doi.org/10.1093/jac/dkr512>
- Khansa, R. M. (2019). Uji aktivitas minyak atsiri bunga cengkeh (*syzygium aromaticum* l.) Dalam menghambat pertumbuhan jamur *Candida albicans* secara in vitro. Politeknik Kesehatan Kementerian Kesehatan, Yogyakarta.
- Mulu, A., Kassu, A., Anagaw, B., Moges, B., Gelaw, A., Alemayehu, M., ... Isogai, E. (2013). Frequent detection of “azole” resistant *Candida* species among late presenting AIDS patients in northwest Ethiopia. *BMC Infectious Diseases*, 13(1), 1. <https://doi.org/10.1186/1471-2334-13-82>
- Murtiastutik, D., & Maharani, C. S. (2019). Profile of *Candida* Resistancy to Fluconazole in Male Patient with Oral Candidiasis and HIV/AIDS. *Journal of AIDS & Clinical ...*, 10(1), 1–6.
- Murtiastutik, Dwi, Prakoswa, C. R. S., Tantular, I. S., Ervianti, E., Hidayati, A. N., & Listiawan, M. Y. (2021). Correlation between CD4 T lymphocyte and candida

- species counts in oral candidiasis patients with HIV / AIDS. *Indian Journal of Forensic Medicine and Toxicology*, 15(1), 1013–1020. <https://doi.org/10.37506/ijfmt.v15i1.13548>
- Musta, R., & Nurliana, L. (2019). Studi Kinetika Efektifitas Minyak Daun Cengkeh (*Syzygium aromaticum*) Sebagai Antifungi *Candida albicans*. *Indo. J. Chem. Res.*, 6(2), 107–114. <https://doi.org/10.30598//ijcr.2019.6-rus>
- Nurdjannah, N., & N., B. (2012). Cloves (2nd ed.). Indonesian Agency for Agriculture Research and Development (IAARD).
- Pinto, E., Vale-Silva, L., Cavaleiro, C., & Salgueiro, L. (2009). Antifungal activity of the clove essential oil from *Syzygium aromaticum* on *Candida*, *Aspergillus* and dermatophyte species. *Journal of Medical Microbiology*, 58(11), 1454–1462. <https://doi.org/10.1099/jmm.0.010538-0>
- Pudjiati, S. R., Ramali, L. M., Hidayati, A. N., Daili, S. F., & Niode, N. J. (2018). Kandidiasis mukokutan pada pasien HIV dan AIDS. In *Manifestasi dan Tatalaksana Kelainan Kulit dan Kelamin pada Pasien HIV/AIDS* (pp. 135–151). Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia.
- Rosana, Y., Yasmon, A., & Lestari, D. C. (2015). Overexpression and mutation as a genetic mechanism of fluconazole resistance in *Candida albicans* isolated from human immunodeficiency virus patients in Indonesia. *Journal of Medical Microbiology*, 64(9), 1046–1052. <https://doi.org/10.1099/jmm.0.000123>
- Sadeghi, G., Ebrahimi-Rad, M., Mousavi, S. F., Shams-Ghahfarokhi, M., & Razzaghi-Abyaneh, M. (2018). Emergence of non-*Candida albicans* species: Epidemiology, phylogeny and fluconazole susceptibility profile. *Journal de Mycologie Medicale*, 28(1), 51–58. <https://doi.org/10.1016/j.mycmed.2017.12.008>
- Sakkas, H., Gousia, P., Petsios, S., Economou, V., & Papadopoulou, C. (2016). Antifungal activity of four essential oils against *Candida* clinical isolates Antibiotic resistance View project Antifungal activity of four essential oils against *Candida* clinical isolates. *Asian Journal of Ethnopharmacology and Medicinal Foods*, (01), 22.
- Schmidt, E., Jirovetz, L., Wlcek, K., Buchbauer, G., Gochev, V., Girova, T., ... Geissler, M. (2007). Antifungal Activity of Eugenol and Various Eugenol-Containing Essential Oils against 38 Clinical Isolates of *Candida albicans*. *Journal of Essential Oil-Bearing Plants*, 10(5), 421–429. <https://doi.org/10.1080/0972060X.2007.10643575>
- Sumalapao, D. E. P., Rippey, C., Atienza, H. B. P., Cabrera, E. C., Flores, M. J. C., Amalin, D. M., ... Gloriani, N. G. (2018). Susceptibility kinetic profile of *Candida albicans* biofilm on latex silicone surfaces with antifungal azoles. *Current Research in Environmental and Applied Mycology*, 8(6), 564–571. <https://doi.org/10.5943/cream/8/6/1>
- Tappuni, A. R. (2020). The global changing pattern of the oral manifestations of HIV. *Oral Diseases*, 26(S1), 22–27. <https://doi.org/10.1111/odi.13469>
- Williams, D. W., Kuriyama, T., Silva, S., Malic, S., & Lewis, M. A. O. (2011). *Candida* biofilms and oral candidosis: Treatment and prevention. *Periodontology* 2000, 55(1), 250–265. <https://doi.org/10.1111/j.1600-0757.2009.00338.x>
- Suryasa, W., Sudipa, I. N., Puspani, I. A. M., & Netra, I. (2019). Towards a Change of Emotion in Translation of Kṛṣṇa Text. *Journal of Advanced Research in Dynamical and Control Systems*, 11(2), 1221–1231.

Sarada, V., & Mallikarjuna, T. (2018). Socio-economic and psychological problems of third gender people living with HIV/AIDS: A study in A.P. *International Journal of Health & Medical Sciences*, 1(1), 10-17.
<https://doi.org/10.31295/ijhms.v1n1.34>

Comparison of antifungal activity of fluconazole and clove leaf essential oil on Candida species isolate in HIV/AIDS patients with oral candidiasis

ORIGINALITY REPORT

17%

SIMILARITY INDEX

11%

INTERNET SOURCES

13%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

1	worldwidescience.org Internet Source	2%
2	www.microbiologyresearch.org Internet Source	1%
3	www.phytojournal.com Internet Source	1%
4	Erich Schmidt, Leopold Jirovetz, Katrin Wlcek, Gerhard Buchbauer et al. "Antifungal Activity of Eugenol and Various Eugenol-Containing Essential Oils against 38 Clinical Isolates of ", Journal of Essential Oil Bearing Plants, 2007 Publication	1%
5	ojs3.unpatti.ac.id Internet Source	1%
6	herbmedpharmacol.com Internet Source	1%
7	G. Sadeghi, M. Ebrahimi-Rad, S.F. Mousavi, M. Shams-Ghahfarokhi, M. Razzaghi-Abyaneh. "Emergence of non- Candida	1%

albicans species: Epidemiology, phylogeny and fluconazole susceptibility profile",
Journal de Mycologie Médicale, 2018

Publication

-
- | | | |
|----|--|------|
| 8 | academicjournals.org
Internet Source | 1 % |
| 9 | David W. Williams. "Candida biofilms and oral candidosis: treatment and prevention : Candida biofilms and oral candidosis",
Periodontology 2000, 02/2011
Publication | 1 % |
| 10 | Najla Alshaikh, Kahkashan Perveen. " Anti-candidal Activity and Chemical Composition of Essential Oil of Clove () ", Journal of Essential Oil Bearing Plants, 2017
Publication | 1 % |
| 11 | Sarah G. Whaley, Elizabeth L. Berkow, Jeffrey M. Rybak, Andrew T. Nishimoto, Katherine S. Barker, P. David Rogers. "Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species", Frontiers in Microbiology, 2017
Publication | 1 % |
| 12 | ejournal.medistra.ac.id
Internet Source | 1 % |
| 13 | Diana L. Zuza-Alves, Walicyranison P. Silva-Rocha, Guilherme M. Chaves. "An Update on Candida tropicalis Based on Basic and | <1 % |

Clinical Approaches", Frontiers in Microbiology, 2017

Publication

14	doaj.org Internet Source	<1 %
15	www.walshmedicalmedia.com Internet Source	<1 %
16	Dilara Devecioglu, Mustafa Turker, Funda Karbancioglu-Guler. " Antifungal Activities of Different Essential Oils and Their Electrospun Nanofibers against and Species Isolated from Bread ", ACS Omega, 2022 Publication	<1 %
17	Anna Marchese, Ramona Barbieri, Erika Coppo, Ilkay Erdogan Orhan et al. "Antimicrobial activity of eugenol and essential oils containing eugenol: A mechanistic viewpoint", Critical Reviews in Microbiology, 2017 Publication	<1 %
18	jacmjournal.org Internet Source	<1 %
19	bmcpharmacoltoxcol.biomedcentral.com Internet Source	<1 %
20	Jung Yun Chang, Yu-Kyoung Oh, Hak Soo Kong, Eun Jung Kim, Dong Deuk Jang, Ki Taek Nam, Chong-Kook Kim. "Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels on	<1 %

21

Alexander, B.D.. "Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures", Diagnostic Microbiology & Infectious Disease, 200604

Publication

<1 %

22

Jehoshua Sharma, Sierra Rosiana, Iqra Razzaq, Rebecca Shapiro. "Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Candida Pathogens", Journal of Fungi, 2019

Publication

<1 %

23

scirp.org
Internet Source

<1 %

24

Abdulaziz Al-Askar, Younes Rashad. "Efficacy of Some Plant Extracts Against Rhizoctonia Solani on Pea", Journal of Plant Protection Research, 2010

Publication

<1 %

25

Muhammad Tahir, Siti Chuzaemi, Eko Widodo, Hafsa Hafsa. "CHEMICAL COMPOUNDS AND ANTIOXIDANT CONTENTS OF CLOVES LEAVES ESSENTIAL OIL", AGROLAND The Agricultural Sciences Journal (e-Journal), 2020

Publication

<1 %

26	Oral Candidosis, 2015. Publication	<1 %
27	Shende, Sneha, Shriyash Patel, Sumit Arora, and Vivek Sharma. "Oxidative Stability of Ghee Incorporated with Clove Extracts and BHA at Elevated Temperatures", International Journal of Food Properties, 2014. Publication	<1 %
28	core.ac.uk Internet Source	<1 %
29	file.scirp.org Internet Source	<1 %
30	ourspace.uregina.ca Internet Source	<1 %
31	uknowledge.uky.edu Internet Source	<1 %
32	www.elejournals.com Internet Source	<1 %
33	www.frontiersin.org Internet Source	<1 %
34	www.scielo.br Internet Source	<1 %
35	Martha F. Mushi, Oliver Bader, Liliane Taverne-Ghadwal, Christine Bii, Uwe Groß, Stephen E. Mshana. "Oral candidiasis among African human immunodeficiency	<1 %

virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa", Journal of Oral Microbiology, 2017

Publication

36

Ajay Kumar, Feroz Khan, Dharmendra Saikia. "Exploration of Medicinal Plants as Sources of Novel Anticandidal Drugs", Current Topics in Medicinal Chemistry, 2019

Publication

<1 %

37

Gomes Dias de Oliveira Simone, Guerra Lund Rafael, Martin Pereira de Pereira Claudio, Piva Evandro. "Anti-candida and anti-enzyme activity and cytotoxicity of 2-phenyl-4H-chromen-4-one", African Journal of Microbiology Research, 2016

Publication

<1 %

38

Mojtaba Didehdar, Zahra Chegini, Aref Shariati. "Eugenol: A novel therapeutic agent for the inhibition of Candida species infection", Frontiers in Pharmacology, 2022

Publication

<1 %

39

Tossaton Charoonratana. "Clove (Syzygium aromaticum) volatiles", Elsevier BV, 2022

Publication

<1 %

Exclude quotes Off

Exclude matches Off

Exclude bibliography On

Comparison of antifungal activity of fluconazole and clove leaf essential oil on Candida species isolate in HIV/AIDS patients with oral candidiasis

GRADEMARK REPORT

FINAL GRADE

/0

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6

PAGE 7

PAGE 8

PAGE 9

PAGE 10

PAGE 11
